Literature DB >> 2375920

Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors.

A Ríos1, M C Cañizo, M A Sanz, T Vallespí, G Sanz, M Torrabadella, F Gomis, C Ruiz, J F San Miguel.   

Abstract

Ten characteristics of bone marrow (BM) biopsies in paraffin sections, obtained at diagnosis from patients with myelodysplastic syndromes (MDS) classified according to the FAB criteria, were analysed to identify both the most relevant morphologic data and any possible influence on survival. Agreement between two observers was obtained for 94% of the data. BM cellularity was increased in 63% of the cases and was higher in refractory anaemia with excess of blasts (RAEB). RAEB in transformation (RAEB-t) and chronic myelomonocytic leukaemia (CMML) (P = 0.001). Dysmegakaryopoiesis and dyserythropoiesis were present respectively in 83% and 72% of the cases, with slight differences among the FAB subtypes. Abnormal localization of immature precursors (ALIP) was found in more than half of the cases and somewhat more frequently seen in the RAEB + RAEB-t + CMML group (P = 0.07). Eosinophilia, plasmacytosis and reticulin fibrosis were evident in 26%, 18% and 47% of the cases respectively. Cellularity (P = 0.006), eosinophilia (P = 0.009) and, to some extent, dysmegakaryopoiesis (P = 0.07) bore a certain relationship with survival on univariate analysis. The presence of ALIP was not seen to affect the outcome. Multivariate analysis showed that the cellularity and presence of dysmegakaryopoiesis, in BM biopsy, added significant independent prognostic information to that achieved with age, platelet count and proportion of blast cells in BM aspirate, three variables with proven prognostic value in MDS patients. Using a regression model including these five characteristics we have stratified the patients into low, intermediate and high-risk groups with different survivals (P = 0.00001). The present findings show that BM biopsy is able to provide both morphological characteristics and information about the prognosis of survival, and should thus be included in the initial evaluation of MDS.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2375920     DOI: 10.1111/j.1365-2141.1990.tb02612.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

Review 1.  Bone marrow histology. 3: Value of bone marrow core biopsy in acute leukaemia, myelodysplastic syndromes, and chronic myeloid leukaemia.

Authors:  D A Winfield; S V Polacarz
Journal:  J Clin Pathol       Date:  1992-10       Impact factor: 3.411

2.  Hypocellular myelodysplastic syndromes: clinical and biological significance.

Authors:  Dragomir Marisavljevic; Vesna Cemerikic; Zoran Rolovic; Darinka Boskovic; Milica Colovic
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

Review 3.  Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics.

Authors:  Aaron C Shaver; Adam C Seegmiller
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

4.  Chromosome analyses in patients with myelodysplastic syndromes: correlation with bone marrow histopathology and prognostic significance.

Authors:  M Werner; H Maschek; V Kaloutsi; H Choritz; A Georgii
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

5.  Myelofibrosis in primary myelodysplastic syndromes: clinical and biological significance.

Authors:  D Marisavljević; Z Rolović; V Cemerikić; D Bosković; M Colović
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

6.  Prognostic relevance of histological findings on bone marrow biopsy in myelodysplastic syndromes.

Authors:  G Lambertenghi-Deliliers; C Annaloro; A Oriani; D Soligo; E Pozzoli; E E Polli
Journal:  Ann Hematol       Date:  1993-02       Impact factor: 3.673

7.  Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis.

Authors:  H Maschek; V Kaloutsi; M Rodriguez-Kaiser; M Werner; H Choritz; K Mainzer; M Dietzfelbinger; A Georgii
Journal:  Ann Hematol       Date:  1993-03       Impact factor: 3.673

Review 8.  FAB classification of myelodysplastic syndromes: merits and controversies.

Authors:  G E Verhoef; S Pittaluga; C De Wolf-Peeters; M A Boogaerts
Journal:  Ann Hematol       Date:  1995-07       Impact factor: 3.673

9.  Comparison of scoring systems in primary myelodysplastic syndromes.

Authors:  H Maschek; R Gutzmer; H Choritz; A Georgii
Journal:  Ann Hematol       Date:  1995-06       Impact factor: 3.673

10.  Myelodysplastic syndrome with myelofibrosis transformed to a precursor B-cell acute lymphoblastic leukemia: a case report with review of the literature.

Authors:  Ayed A Algarni; Mojtaba Akhtari; Kai Fu
Journal:  Case Rep Hematol       Date:  2012-03-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.